DECIPHERA PHARMACEUTICALS INC

DCPH NASDAQ

Champion-Vibe

LONG-TERM: 4hr classic bullish divergence, Daily MACD quadruple classic bullish divergence and RSI divergence, Bullish cypher harmonic pattern (not perfect), and over a critical support. The white line is a place to take some profits but $64.69 is the real long term target (not financial advice)

kunjalhp41590

DCPH Bullish Shark Pattern with Hidden bullish divergence on MACD and RSI. Also Hidden divergence on 4hr. Good r/r. NFA. Do your own DD.

ProjectSyndicate

Why get subbed to to me on Tradingview? -TOP author on TradingView -15+ years experience in markets -Professional chart break downs -Supply/Demand Zones -TD9 counts / combo review -Key S/R levels -No junk on my charts -Frequent updates -Covering FX/crypto/US stocks -24/7 uptime so constant updates DCPH 2D:: Best level to BUY // 150%+ SWING trade...

mroberts1204

Clinical-stage biotech company so be careful. But nice ascending triangle to trade. Need to see a close above $70 or a high volume pop to enter long. Would like to see one more low volume, shallow pullback before the break.

CoryMitchell-CMT

Deciphera Pharmaceuticals (DCPH) is forming a triangle after a big run-up. This is not a trade yet. Ideally, I want to see the stock consolidate near the top of the triangle. Otherwise, I want to see a strong move out of the triangle on a one-day move with the price closing near its daily highs and well outside the pattern. I am looking for an initial target near...

KAS109

Pure technical trade based on R/R and nothing else Today appears favoring bulls, hopefully everyone who wanted out gots flushed out on that waterfall. RSI and CCI in uptrend and confirming so far. Setting alert for price to close above 5 ema, needs at least one more day of consolidation for proof.

Anbat

Once PA finds support after INSIDERS, sell some of their initial shares for a profit from $17.00, then it will be time to go long again. Patience Is Key!! IPO Lockup Expiration will be on 3/27/2028 (Tuesday) and TREND is bearish, stay on it until PA proves it has found a SUPPORT level.

Anbat

WALTHAM, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the closing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds from the...